Journals / Tüberküloz ve Toraks / 2007 / Cilt: 55 - Sayı: 2

Solunum hastalığı olanlarda eşlik eden hastalıklar

Co-morbid illnesses in patients with respiratory disease

Pages
127–134
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Being aware of the co-morbid illnesses will allow improved management and the planning of appropriate support to a wide range of elderly patients with respiratory disease with important and peculiar needs for care.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:With the rising age, more patients will be diagnosed with one or more other serious illnesses.
📊
Key Findings & Data:We performed chart review of 2764 patients with respiratory disease who admitted in three hospitals in Japan between January 1990 and March 2005.
💡
Conclusion & Impact:Being aware of the co-morbid illnesses will allow improved management and the planning of appropriate support to a wide range of elderly patients with respiratory disease with important and peculiar needs for care.
🔬Design:Review & Systematic Survey
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

With the rising age, more patients will be diagnosed with one or more other serious illnesses. This study was undertaken to evaluate the frequency of co-morbid illnesses in patients with respiratory diseases, and to compare the frequency between the elderly and the younger patients. We performed chart review of 2764 patients with respiratory disease who admitted in three hospitals in Japan between January 1990 and March 2005. Co-morbid illnesses were observed in 69.5% of 2764 patients with respiratory disease. In 1150 patients 70 years or older, 83.9% of them had co-morbid illnesses. The prevalence of co-morbid illnesses in patients with respiratory disease clearly rose with increasing age (p= 0.0001), the largest increase occurring after the age of 50. Charlson index in patients with respiratory disease clearly rose with increasing age (p= 0.0001). In both elderly (≥ 70 years) or younger (< 70 years) groups of patients, co-morbid illnesses did not influence on the choice of diagnostic procedure. Although the presence of co-morbid illnesses in our patients with non-malignant respiratory disease did not influence on the choice of treatment, however, the presence of co-morbid illnesses in elderly patients with malignant respiratory disease apparently discouraged the choice of standard therapy. Clinical research should address appropriate therapies not only for the elderly patients without co-morbid illness but also for those with co-morbid illnesses. Being aware of the co-morbid illnesses will allow improved management and the planning of appropriate support to a wide range of elderly patients with respiratory disease with important and peculiar needs for care.

Özet

İlerleyen yaşla birlikte daha fazla sayıda hastaya bir veya daha fazla ciddi hastalık tanısı konulacaktır. Bu çalışma solunum sistemi hastalığı olan hastalarda eşlik eden hastalık sıklığının değerlendirilmesi, yaşlı ve daha genç hastalardaki eşlik eden hastalık sıklığını karşılaştırmak üzere yapıldı. Japonya’da Ocak 1990-Mart 2005 tarihleri arasında üç hastaneye başvuran 2764 hastanın dosya incelemesi yapıldı. Solunum hastalığı olan 2764 hastanın %69.5’inde eşlik eden hastalık saptandı. Yetmiş yaş ve üstünde olan 1150 hastanın %83.9’unda ek hastalık vardı. Solunum sistemi hastalığı olan hastalarda eşlik eden hastalık prevalansının açıkça arttığı (p= 0.0001), en fazla artışın 50 yaş sonrasında ortaya çıktığı bulundu. Solunum sistemi hastalığı olanlarda artan yaşla birlikte Charlson indeksi yüksekti (p= 0.0001). Hem yaşlı (≥ 70 yaş) hem de genç (< 70 yaş) gruptaki hastalarda, eşlik eden hastalıkların tanısal prosedür seçimini etkilemediği belirlendi. Malignite dışı solunum hastalığı olanlarda ek hastalık varlığı tedavi kararını etkilememekle beraber malignitesi olan yaşlı hastalarda ek hastalık olmasının standart tedavi kararını olumsuz olarak etkilediği saptandı. Klinik araştırma sadece eşlik eden hastalığı olmayan yaşlı hastalarda uygun tedavileri değil ayrıca ek hastalığı olanları da kapsamalıdır. Ek hastalıkların farkında olunması özel ve dikkatli bakım gerektiren solunum hastalığı olan geniş bir yaşlı hasta grubunda uygun desteğin planlanmasına ve yeterli tedavi uygulanmasını sağlayacaktır.

🔖

Cite This Article

KANEMOTO, K., SATOH, H., ISHIKAWA, H., OHTSUKA, M., SUMI, M. (2022). Solunum hastalığı olanlarda eşlik eden hastalıklar. Tüberküloz ve Toraks, Cilt: 55 - Sayı: 2, 127–134. https://ajindex.com/articles/618304

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Incalzi RA, Fuso L, De Rosa M, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 2794-800
  2. Janssen-Heijnen ML, Schipper RM, Razenberg PP, et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: A population-based study. Lung Cancer 1998; 21: 105-13
  3. Ruiz M, Ewig S, Marcos MA, et al. Etiology of communityacquired pneumonia: Impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397-405
  4. Kurishima K, Satoh H, Ishikawa H, et al. Lung cancer in the octogenarians. Gerontology 2001; 47: 158-60
  5. Menendez R, Ferrando D, Valles JM, et al. Initial risk class and length of hospital stay in community-acquired pneumonia. Eur Respir J 2001; 18: 151-6
  6. Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidities and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 52: 1047-57
  7. Firat S, Byhardt RW, Gore E. Comorbidities and Karnofsky performance score are independent prognostic factors in stage III non-small-cell lung cancer: An institutional analysis of patients treated on four RTOG studies. Int J Radiat Oncol Biol Phys 2002; 54: 357-64
  8. Lopez-Encuentra A, Bronchogenic Carcinoma Co-operative Group. Comorbidity in operable lung cancer. A multicenter descriptive study on 2992 patients. Lung Cancer 2002; 35: 263-9
  9. Ludbrook JJ, Truong PT, MacNeil MV, et al. Do age and comorbidity impact treatment allocation and outcomes in limited stage small-cell lung cancer? A community-based population analysis. Int J Radiat Oncol Biol Phys 2003; 55: 1321-30
  10. Weiss ST, DeMeo DL, Postma DS. COPD: Problems in diagnosis and measurement. Eur Respir J 2003; 21(Suppl 41): 4-12
  11. Kinnunen T, Saynajakangas O, Tuuponen T, Keistinen T. Impact of comorbidities on the duration of COPD patients’ hospital episodes. Respir Med 2003; 97: 143-6
  12. Janssen-Heijnen ML, Smulders S, Lemmens VE, et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004; 59: 602-7
  13. Scala R, Bartolucci S, Naldi M, et al. Co-morbidity and acute decompensations of COPD requiring non-invasive positive-pressure ventilation. Intensive Care Med 2004; 30: 1747-54
  14. Anto JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17: 982-94
  15. American Thoracic Society/European